03:03:51 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-21 X-dag ordinarie utdelning HLUN A 0.70 DKK
2024-03-21 X-dag ordinarie utdelning HLUN B 0.70 DKK
2024-03-20 Årsstämma 2024
2024-02-07 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-16 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-03-22 X-dag ordinarie utdelning HLUN A 0.58 DKK
2023-03-22 X-dag ordinarie utdelning HLUN B 0.58 DKK
2023-03-21 Årsstämma 2023
2023-02-08 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Split HLUN B 1:5
2022-06-08 Extra Bolagsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-03-24 X-dag ordinarie utdelning HLUN B 2.00 DKK
2022-03-23 Årsstämma 2022
2022-02-09 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-11 Kvartalsrapport 2021-Q1
2021-03-24 X-dag ordinarie utdelning HLUN B 2.50 DKK
2021-03-23 Årsstämma 2021
2021-02-04 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-12 Kvartalsrapport 2020-Q1
2020-03-25 X-dag ordinarie utdelning HLUN B 4.10 DKK
2020-03-24 Årsstämma 2020
2020-02-06 Bokslutskommuniké 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-08-14 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-27 X-dag ordinarie utdelning HLUN B 12.00 DKK
2019-03-26 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-08 Kvartalsrapport 2018-Q1
2018-03-21 X-dag ordinarie utdelning HLUN B 8.00 DKK
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-09 Kvartalsrapport 2017-Q2
2017-05-10 Kvartalsrapport 2017-Q1
2017-03-31 X-dag ordinarie utdelning HLUN B 2.45 DKK
2017-03-30 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-11-02 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-11 Kvartalsrapport 2016-Q1
2016-04-01 X-dag ordinarie utdelning HLUN B 0.00 DKK
2016-03-31 Årsstämma 2016
2016-02-10 Bokslutskommuniké 2015
2015-11-04 Kvartalsrapport 2015-Q3
2015-08-19 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-03-26 X-dag ordinarie utdelning HLUN B 0.00 DKK
2015-03-25 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-07 Kvartalsrapport 2014-Q2
2014-05-07 Kvartalsrapport 2014-Q1
2014-03-27 X-dag ordinarie utdelning HLUN B 2.77 DKK
2014-03-26 Årsstämma 2014
2014-02-06 Bokslutskommuniké 2013
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-07 Kvartalsrapport 2013-Q2
2013-05-01 Kvartalsrapport 2013-Q1
2013-03-22 X-dag ordinarie utdelning HLUN B 2.00 DKK
2013-03-21 Årsstämma 2013
2013-02-06 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-08 Kvartalsrapport 2012-Q2
2012-05-02 Kvartalsrapport 2012-Q1
2012-03-30 X-dag ordinarie utdelning HLUN B 3.49 DKK
2012-03-29 Årsstämma 2012
2012-02-08 Bokslutskommuniké 2011
2011-11-09 Kvartalsrapport 2011-Q3
2011-08-10 Kvartalsrapport 2011-Q2
2011-05-04 Kvartalsrapport 2011-Q1
2011-03-31 X-dag ordinarie utdelning HLUN B 3.77 DKK
2011-03-30 Årsstämma 2011
2010-04-21 X-dag ordinarie utdelning HLUN B 3.07 DKK
2009-04-22 X-dag ordinarie utdelning HLUN B 2.30 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Lundbeck är ett läkemedelsbolag. Störst fokus återfinns inom forskning om psykiatriska och neurotiska störningar, vilket innefattar behandling av depression, schizofreni, Alzheimers och Parkinsons syndrom. Bolaget bedriver forskning, utveckling och distribution av läkemedel där kundbasen återfinns på global nivå. Bolaget grundades ursprungligen under 1915 och har sitt huvudkontor i Valby.
2023-02-10 15:13:08

Valby, Denmark, 10 February 2023 - H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

+--+-----------------+----------+---------+
|1.|Details of the |
| |person |
| |discharging |
| |managerial |
| |responsibilities |
| |/ person closely |
| |associated |
+--+-----------------+----------+---------+
|a)|Name |Johan Luthman |
+--+-----------------+----------+---------+
|2.|Reason for the |
| |notification |
+--+-----------------+----------+---------+
|a)|Position/status |Executive Vice |
| | |President, Research |
| | |& Development |
+--+-----------------+----------+---------+
|b)|Initial |Initial notification|
| |notification/Amen| |
| |dment | |
+--+-----------------+----------+---------+
|3.|Details of  the |
| |issuer,  |
| |emission  |
| |allowance  |
| |market |
| |participant, |
| |auction |
| |platform, |
| |auctioneer or |
| |auction monitor |
+--+-----------------+----------+---------+
|a)|Name |H. Lundbeck A/S |
+--+-----------------+----------+---------+
|b)|LEI code |5493006R4KC2OI5D3470|
+--+-----------------+----------+---------+
|4 |Details of the |
| |transaction(s): |
| |section to be |
| |repeated for (i) |
| |each type of |
| |instrument; (ii) |
| |each type of |
| |transaction; |
| |(iii) each date; |
| |and (iv) each |
| |place where |
| |transactions |
| |have been |
| |conducted |
+--+-----------------+----------+---------+
|a)|Description of |Shares |
| |the financial | |
| |instrument, type |H. Lundbeck A/S, B |
| |of instrument |-shares: |
| |Identification |DK0061804770 |
| |code | |
+--+-----------------+----------+---------+
|b)|Nature of the |Purchase of shares |
| |transaction | |
+--+-----------------+----------+---------+
|c)|Price(s) and |Price(s) |Volume(s)|
| |volume(s) | | |
+--+-----------------+----------+---------+
| | |DKK  29.84| 8,399 |
+--+-----------------+----------+---------+
|d)|Aggregated | |
| |information | |
| |- Aggregated | |
| |volume | |
| |- Price | |
+--+-----------------+----------+---------+
|e)|Date of the |2023-02-10 |
| |transaction | |
+--+-----------------+----------+---------+
|f)|Place of the |NASDAQ Copenhagen |
| |transaction |XCSE |
+--+-----------------+----------+---------+

+--+-----------------+---------------------+----------------------------------+
|1.|Details of the |
| |person |
| |discharging |
| |managerial |
| |responsibilities |
| |/ person closely |
| |associated |
+--+-----------------+---------------------+----------------------------------+
|a)|Name |Jacob Tolstrup |
+--+-----------------+---------------------+----------------------------------+
|2.|Reason for the |
| |notification |
+--+-----------------+---------------------+----------------------------------+
|a)|Position/status |Executive Vice |
| | |President, Commercial |
| | |Operations |
+--+-----------------+---------------------+----------------------------------+
|b)|Initial |Initial notification |
| |notification/Amen| |
| |dment | |
+--+-----------------+---------------------+----------------------------------+
|3.|Details of  the |
| |issuer,  |
| |emission  |
| |allowance  |
| |market |
| |participant, |
| |auction |
| |platform, |
| |auctioneer or |
| |auction monitor |
+--+-----------------+---------------------+----------------------------------+
|a)|Name |H. Lundbeck A/S |
+--+-----------------+---------------------+----------------------------------+
|b)|LEI code |5493006R4KC2OI5D3470 |
+--+-----------------+---------------------+----------------------------------+
|4 |Details of the |
| |transaction(s): |
| |section to be |
| |repeated for (i) |
| |each type of |
| |instrument; (ii) |
| |each type of |
| |transaction; |
| |(iii) each date; |
| |and (iv) each |
| |place where |
| |transactions |
| |have been |
| |conducted |
+--+-----------------+---------------------+----------------------------------+
|a)|Description of |Shares |
| |the financial | |
| |instrument, type |H. Lundbeck A/S, A |
| |of instrument |-shares: DK0061804697 |
| |Identification | |
| |code |H. Lundbeck A/S, B |
| | |-shares: DK0061804770 |
+--+-----------------+---------------------+----------------------------------+
|b)|Nature of the |Sale of shares |
| |transaction | |
+--+-----------------+---------------------+----------------------------------+
|c)|Price(s) and |Price(s) |Volume(s) |
| |volume(s) | | |
+--+-----------------+---------------------+----------------------------------+
| | |DKK 26.90 (A-shares) |A-shares: 7,536   B-shares: 28,000|
| | | DKK 29.04 (B-shares)| |
+--+-----------------+---------------------+----------------------------------+
|d)|Aggregated | |
| |information | |
| |- Aggregated | |
| |volume | |
| |- Price | |
+--+-----------------+---------------------+----------------------------------+
|e)|Date of the |2023-02-09 |
| |transaction | |
+--+-----------------+---------------------+----------------------------------+
|f)|Place of the |NASDAQ Copenhagen |
| |transaction |XCSE |
+--+-----------------+---------------------+----------------------------------+

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:
  • spouse or cohabitant
  • dependent children
  • legal entities in which the executive has a controlling influence.

 

Lundbeck contacts

Investors:                                    Media:
Palle Holm Olesen Thomas Mikkel
Mortensen
Vice President, Investor Relations Media Relations Lead,
Corporate
Communication
PALO@lundbeck.com THMR@lundbeck.com
+45 30 83 24 26 +45 30 83 30 24

About H. Lundbeck A/S

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Instagram (h_lundbeck), Twitter at @Lundbeck andvia LinkedIn.